Glaukos opened at $242.42, in line with its previous close of $242.48. In the last trading session, the stock traded between $237.05 and $248.75. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Glaukos is now worth
$ 524.92
giving a profit of
$ 424.92 (424.92%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-2.54 (-1.05%)
Day High
$248.75
Day Low
$237.05
Day Open
$242.42
Prev Close
$242.48
Volume
5,90,470
1W Return
35.70%
1M Return
51.50%
3M Return
48.00%
6M Return
105.15%
1Y Return
211.25%
Market Cap ($ Mn)
14,204
PE Ratio
-
PB Ratio
15.51
PEG Ratio
-
ROE
-25.22%
ROCE
-22.58%
EPS (TTM)
$0.03
1 Week
35.70%
1 Month
51.50%
3 Months
48.00%
6 Months
105.15%
9 Months
101.51%
Glaukos reports positive three-year Epioxa results for keratoconus treatment
Glaukos Corporation announced positive three-year topline results for its keratoconus therapy Epioxa. Treated eyes showed a sustained 1.9 diopter improvement in maximum corneal curvature from baseline. 29% of eyes gained two or more lines of best-corrected visual acuity at year 3. The study reported no serious adverse events or discontinuations due to adverse events over three years.
22 days agoGlaukos Q3FY26 Results: Earnings release scheduled for October 28
Glaukos Corporation releases Q3 2026 financial results on October 28, 2026. Conference call and webcast scheduled for 1:30 pm PT on the same day. Company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases. Commercial launch of iDose TR commenced in 2024.
23 days agoGlaukos shares deliver 16.15% annualized return over last 10 years
Glaukos Corporation posted a 16.15% average annual return over the past 10 years. The stock outperformed the market by 2.33% on an annualized basis. A $1,000 investment made 10 years ago is now worth $4,257.97. Current market capitalization stands at $9.53 billion with a share price of $161.59.
23 days agoGlaukos stock up 221% in five years with 26.17% annualized returns
Glaukos delivered an annualized return of 26.17% over the past five years. Stock outperformed the broader market by 15.09% on an annualized basis. A $100 investment five years ago is now worth $321.19. Current market capitalization stands at $10.97 billion.
2mo agoGlaukos to present at Wells Fargo Healthcare Conference in Boston
Glaukos Corporation confirmed its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The event offers investors a direct channel to engage with management regarding the company's ophthalmic therapies and pipeline progress.
2mo agoGlaukos Q2 Results: Sales surge 49.54% YoY to $185.610M
Glaukos delivered a strong second-quarter performance, with adjusted EPS of $(0.14) beating estimates by 36.36 percent. Revenue surged 49.54 percent year-over-year to $185.610 million, significantly exceeding the $150.978 million consensus. The results reflect narrowing losses and robust top-line growth.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 |
An investment of $100 made 5 years ago in Glaukos is now worth
$ 524.92
giving a profit of
$ 424.92 (424.92%)
Note: Past profits do not guarantee future returns.
